Bristol-Myers Squibb Co

Quantli Newsdesk

· 18 days ago

AstraZeneca's $264B bid for $133B Bristol Myers defies its own growth narrative-acquirer takes on patent cliffs generating half of target's revenue while analysts question why a best-in-class pipeline needs financial engineering through a low-multiple legacy portfolio.

Quantli Newsdesk

· 3 months ago

Bristol-Myers Squibb entered a global partnership with Hengrui Pharma valued at up to $15.2 billion, combining 13 early-stage programs across oncology, hematology, and immunology. The deal includes a $600 million upfront payment and splits global development rights, with Hengrui leading early clinical work and BMS retaining worldwide rights outside China. The collaboration aims to accelerate proof-of-concept research while diversifying both companies' pipelines.

10-K

Quantli Newsdesk

· 4 months ago

BMS reported flat revenues of $48.2 billion with a 17% increase in the Growth Portfolio offset by legacy product generic erosion. GAAP EPS improved from a loss of $4.41 to $3.46, driven by significantly lower acquisition-related charges and strategic cost savings.